ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs MXN
16.7855
0.03%
Brent Oil
82.585
0.00%
Bitcoin
61,260.01
0.76%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) Noticias

VNDA

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VNDA
FechaHoraFuenteTítuloSímboloCompañía
09/05/202416:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202406:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202415:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202410:16PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202415:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202407:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
22/04/202418:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202409:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202408:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202409:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
02/04/202417:10PR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202415:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202406:00PR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
04/03/202420:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
16/02/202415:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/02/202406:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VNDAVanda Pharmaceuticals Inc
07/02/202415:02PR Newswire (US)Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202415:30PR Newswire (US)Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
31/01/202408:00PR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of OnychomycosisNASDAQ:VNDAVanda Pharmaceuticals Inc
30/01/202411:35PR Newswire (US)Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/01/202421:05PR Newswire (US)Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.NASDAQ:VNDAVanda Pharmaceuticals Inc
25/01/202412:07PR Newswire (US)Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and HepatologyNASDAQ:VNDAVanda Pharmaceuticals Inc
23/01/202410:52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VNDAVanda Pharmaceuticals Inc
23/01/202408:15PR Newswire (US)Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2SNASDAQ:VNDAVanda Pharmaceuticals Inc
19/01/202415:57Dow Jones NewsVanda Pharma's Trade Secrets Suit Against FDA Moves ForwardNASDAQ:VNDAVanda Pharmaceuticals Inc
19/01/202414:56PR Newswire (US)Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug AdministrationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/01/202414:46PR Newswire (US)Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical PsychiatryNASDAQ:VNDAVanda Pharmaceuticals Inc
12/01/202411:21PR Newswire (US)Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved DrugsNASDAQ:VNDAVanda Pharmaceuticals Inc
04/01/202415:30PR Newswire (US)Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare ConferenceNASDAQ:VNDAVanda Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VNDA

Su Consulta Reciente

NYSE
CVX
Chevron
NASDAQ
AAPL
Apple
PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
AMEX
XLF
Financial Select Sector
USOTC
BASFY
BASF (QX)
USOTC
RHHBY
Roche (QX)
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
CCOM
OILBRENT
Brent Oil
NYSE
VZ
Verizon Communications
USOTC
ADDYY
Adidas (QX)
NYSE
KO
Coca Cola
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados